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Abstract To determine whether the expression of different 
PDE4D variants is unique to the rat or conserved through 
evolution, we have characterized the different PDE4D mRNAs 
expressed in human peripheral blood mononuclear cells. RT- 
PCR was performed using primers based on rat sequences and 
mRNAs from mononuclear cells. The specifically amplified 
fragments had a size identical to that predicted for rat PDEAD1, 
PDE4D2 and PDE4D3. Sequencing confirmed that these 
fragments are derived from the human PDE4D gene. Their 
sequence was highly homologous to that reported for the rat 
variants, cDNAs corresponding to the entire ORF of human 
PDE4D2 and PDFAD3 were expressed in mammalian cells, 
causing a large increase in PDE activity. Western blot analysis 
of human peripheral blood mononuclear cell extracts demon- 
strated the presence of proteins corresponding to the recombinant 
PDE4D1 and PDE4D2. The pattern of splicing and different 
promoter usage of the PDE4D gene is therefore conserved uring 
evolution, which indicates an important physiological role. 
Key words: Cyclic AMP; cAMP-phosphodiesterase; 
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1. Introduction 
The intracellular levels of cAMP play a key role in the 
function of inflammatory and immune cells, since an increase 
in this second messenger suppresses a broad array of re- 
sponses in these cells [1-3]. Activation of adenylyl cyclase 
[4-7] or inhibition of phosphodiesterases [8], the enzymes 
that hydrolyse cAMP, suppresses the proliferation of T lym- 
phocytes. This cAMP-dependent inhibition is mediated by the 
type I PKA [9]. Immunocytochemistry and immunoprecipita- 
tion studies on T lymphocytes have shown that cAMP induces 
the translocation of type I PKA and promotes its interaction 
with the antigen specific T cell receptor-CD3 complex [10]. It 
has been hypothesized that a type I PKA-mediated phosphor- 
ylation may induce uncoupling of TCR-CD3 complex from 
the intracellular t ansduction pathways [10]. Additional early 
steps in T lymphocyte activation, such as stimulation of phos- 
pholipase C and tyrosine phosphorylation f the ppl00 phos- 
phoprotein, are inhibited by an increase in intracellular cAMP 
[11]. Finally, a role of cAMP in the inhibition of c-Jun N- 
terminal kinase has been recently demonstrated, indicating an 
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additional crucial step in the pathway that causes inhibition of 
T lymphocyte proliferation [12]. 
Cyclic nucleotide phosphodiesterases [13,14], including the 
enzymes of the PDE4 family (cAMP-phosphodiesterases), 
control cAMP-levels in lymphocytes and monocytes, and 
therefore modulate cellular responses to different stimuli 
[15]. The identification of the PDE4 expressed in immune cells 
is of major interest from a therapeutical point of view, as well 
as for understanding immunological disorders [15]. 
Four PDE4 genes (PDE4A, PDE4B, PDE4C, PDE4D) are 
expressed in rat [16-19], mouse [20], and human [21-25], and 
their characterization has shown a close relationship between 
genes from two different species [14]. Furthermore, for three 
out of four rat and human genes, multiple mRNA variants 
and corresponding protein products have been detected 
[13,14]. The pattern of expression of multiple variants from 
the rat PDE4D gene [26,27] has shown that the heterogeneity 
of the different mRNAs lies in the 5' region. The correspond- 
ing protein variants contain a common region encoded by 
exons 2 to 11 [26], and divergent amino-terminal regions de- 
rived from the assembly of different upstream exons [27]. The 
rat PDE4D1 and PDE4D2 mRNAs are generated by start 
sites controlled by an intronie promoter which is active in 
Sertoli and FRTL-5 cells [28]. These two variants differ in 
the alternate splicing of a short intron, producing a frameshift 
that affects the first in frame AUG codon [26]. Another var- 
iant, rat PDE4D3, detected in the brain and FRTL-5 cells, is 
derived from the activity of a different promoter and the tran- 
scription of upstream exons [27]. The human counterpart of 
this latter form has been described by Bolger et al. [22]. A 
fourth variant (PDE4D4) was also detected in human [22] and 
rat (Vicini, E. and Conti, M., unpublished results), suggesting 
the presence of a third, distinct promoter. Hormones control 
the activation and expression of the PDE4D variants through 
an increase in intracellular cAMP levels. PDE4D3 is activated 
by a PKA-mediated phosphorylation i  FRTL-5 rat thyroid 
cells [27,29,30] and in U937 human monocytic cells [31]. 
Chronic hormonal stimulation induces the synthesis of rat 
PDE4D1 and PDE4D2 in FRTL5 cells [27,29] and Sertoli 
cells [32]. The expression of these two variants is important 
for the long term desensitization of these cells to hormones 
[301. 
This study was undertaken to determine whether the multi- 
plicity of variants arising from the PDE4D gene is conserved 
from rodents to humans during evolution and whether the 
PDE4D gene could take part in the regulation of cAMP levels 
in human peripheral blood mononuclear cells. For this pur- 
pose, we have characterized different PDE4D mRNAs and the 
corresponding proteins expressed in these cells by RT-PCR 
and Western blot analysis. 
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2. Materials and methods 
2.1. Cell isolation and rna preparation 
Human mononuclear cells were prepared from the peripheral blood 
of healthy volunteers according to Boyum et al. [33], using Histopa- 
que-1077 as the separating medium (Sigma). Poly(A) + RNA was pur- 
ified by chromatography on oligo(dT)-cellulose using Pharmacia 
Quick Prep Micro mRNA purification columns. Total RNA was ex- 
tracted using RNAzol (Tel-Test Inc.) according to the manufacturer's 
recommendations. 
2.2. Polymerase chain reaction amplifications and Southern blot analy- 
sis 
First-strand cDNA was generated using Pharmacia cDNA synthesis 
kit, according to the supplied protocol. 0.2 lag of poly(A) + RNA or 
0.8 lag of total RNA were reverse-transcribed with Moloney murine 
leukemia virus reverse transcriptase using random hexadeoxynucleo- 
tides as primers. The complete first-strand cDNA reaction product 
was directly amplified by PCR. The primers used were oligonucleotide 
A, 5'-AATATGAAGGAGCAGCCC-3', corresponding to the 5' end 
sequence of rat PDE4D1 and rat PDE4D2; oligonucleotide B, 5'- 
GTACGGCAGGATGGCCCC-3', corresponding to a sequence in 
intron A of rat PDE4D1 [26]; oligonucleotide C, 5'-CCTCTTGAA- 
CTTGTTGGAGG-3', corresponding to the antisense sequence of rat 
PDE4D at the boundary between exons 2 and 3 [26]; oligonucleotide 
D, 5'-TGCCCACGATAGCTGCTCAAACAAG-3', corresponding 
to the 5' end sequence of rat PDE4D3; and oligonucleotide COM2, 
5'-TCCAGACACCAGTCCAGCTCCTCCA-3', corresponding to the 
antisense sequence of rat PDE4D in a common region of the 3 var- 
iants. GenBank accession numbers for rat PDE4D1, PDE4D2, 
PDE4D3 sequences are: M25349, U09456, U09457. PCRs were per- 
formed in a volume of 50 lal, containing 50 mM KCI, 25 mM Tris- 
HC1 pH 8.3, 2.4 mM MgC12, 0.01% gelatin, 10 pmol of each primer, 
0.18 mM of each dNTP, and 2.5 units of Taq polymerase from Gibco 
BRL. The reactions were performed for 30 thermal cycles consisting 
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of 1 min at 95°C, 1 min at 55°C, 2 min at 72°C. An aliquot of PCR 
product was analyzed on 1.4% agarose gel in 90 mM Tris borate, 2.5 
mM EDTA and stained with ethidium bromide. DNA bands were 
transferred onto a Nylon membrane (ICN), and the membrane was 
hybridized by using the oligonucleotide COM1 (5'-TGGCCAGT- 
TTCTGGTAGGCCTCCTC-3') labelled with [7-32P]ATP (DuPont 
NEN) and T4 polynucleotide kinase (Promega), as previously de- 
scribed [34]. 
2.3. Subcloning and sequencing 
The two DNA bands amplified with the oligonucleotides A and C 
(corresponding to the 5' ends of PDE4D1 and PDE4D2), and the 
band amplified with the oligonucleotides D and COM2 corresponding 
to the 5' end of PDE4D3, were purified from agarose gel by using 
Sephagias BandPrep kit (Pharmacia), and subcloned into pUC18 vec- 
tor using SureClone ligation kit (Pharmacia). The three DNA frag- 
ments were then sequenced using the TAQuence Cycle Sequencing kit 
(United States Biochemical). 
2.4. PDE4D cDNA cloning 
A cDNA containing the entire predicted ORF of human PDE4D2 
was obtained by a single RT-PCR amplification using oligonucleotide 
A and oligonucleotide E, 5'-GCACTGTTACGTGTCAGGAGAAC- 
GATC-3', corresponding to the 3'-end antisense sequence of human 
PDE4D3 ([22], GenBank accession umber: L20970). Amplification 
conditions were the same as above. The ,~ 1.7 kb fragment obtained 
was inserted in the pUC18 vector at the SmaI site, and was then 
released from the vector using EcoRI and XbaI. The PDE4D2 
cDNA was then inserted in the pCMV5 expression vector at the 
EcoRI and XbaI sites of the polylinker. A cDNA encoding the entire 
human PDE4D3 ORF was constructed by ligating a fragment corre- 
sponding to the specific PDE4D3 5' end and a fragment correspond- 
ing to the PDE4D common region, taking advantage of a unique StuI 
site adjacent to the splicing boundary common to the three PDE4D 
variants. For this purpose, the PCR-amplified PDE4D3 5' end in- 
serted in pUC18 vector was released using EcoRI and StuI. A frag- 
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Fig. 1. RT-PCR amplification of the 5' ends of the different human PDE4D variant cDNAs. The primer pair A+C is specific to the PDE4D1 
and PDE4D2 cDNAs. The primer pair B+C is specific to PDE4D1 cDNA. The primer pair D+COM2 is specific to PDE4D3 cDNA. The con- 
trol amplifications were performed in the absence of mRNA (-RNA), or in the absence of reverse transcriptase in the cDNA synthesis tep 
(-RT). The amplification products were electrophoresed on agarose gel, and stained with ethidium bromide. After transfer to membrane, the 
specificity of amplification was assessed by hybridization with the radiolabeled oligonucleotide COM1. Ethidium bromide staining revealed three 
amplified bands with primers D+COM2. Only the band of the expected size (563 bp) hybridized with COM1. With the other primer pairs, the 
size of the observed bands matched the ones expected on the basis of rat sequences (A+C: 175 and 261 bp; B+C: 208 bp). 
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pr imer  A ~ 
PDE4DI  AATATC-AAGGAGCAGCCCTCATGTGCCGGCACCGGGCATCCGAGCATGGC -50 
llllliIlltlllltllliIltlli1111iitttllllililtiltill 
PDE4D2 AATATGAAGGAGCAGCCCTCATGTGCCGGCACCGGGCATCCGAGCATGGC -50 
__~ pr imer  B ~ ~ ~ ~ 
PDE4DI  GGGGTATGGCAGGATGGCCCCCTTTGAACTCGCTAGCGGACCCGTGAAGC - i00 
Ill 
PDE4D2 GGG ( in t ron  A)  -53 
, .'1" Stu• I
PDE4DI  GCTTGA~AACTGAGTCCCCCTTTCCCTGTCTCTTCGCAGAGGAGGCCTAC -150 
liilllillil 
P DE 4 D 2 AGGAGGCCTAC - 64 
PDE4DI  CAGAAACTGGCCAGCGAGACCCTGGAGGAGCTGGACTGGTGTCTGGACCA -200 
lllilllltliilillilllillilillllllliltlillilllllltll 
PDE4D2 CAGAAACTGGCCAGCGAGACCCTGGAGGAGCTGGACTGGTGTCTGGACCA -114 
pr imer  COMI ~ pr imer  COM2 
PDE4DI  GCTAGAGACCCTACAGACCAGGCACTCCGTCAGTGAGATGGCCTCCAACA-250 
lililillillittililllIiIIlllliillttiilIllllliliilll 
PDE4D2 GCTAGAGACCCTACAGACCAGGCACTCCGTCAGTGAGATC~-=CCTCCAACA-164 
\ p r imer  C 
PDE4DI  AGTTTAAAAGGAT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  -263 
ilillililflll 
PDE4D2 AGTTTAAAAGGAT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  -177 
Fig. 2. Nucleotide sequence of the 5' ends of human PDE4D1 and human PDE4D2 cDNAs amplified by RT-PCR from human blood mono- 
nuclear cell mRNA. The entire sequences of the fragments amplified with the primer pair A+C are shown. The position of intron A [26] is in- 
dicated by a dashed line in the PDE4D2 sequence. Asterisks indicate a nucleotide different from rat sequence. The putative initiation ATG co- 
dons for PDE4D1 and PDE4D2 are indicated by bold characters. The point of divergence between PDFAD1, PDE4D2 and PDE4D3 mRNAs 
(5' boundary of exon 2 [26]) is indicated by a downward arrow. The putative boundary between exons 2 and 3 [26] is indicated by an upward 
arrow. The position of a StuI site common to all three PDE4D variants and used for construction of PDE4D3 cDNA is shown. 
ment corresponding to the region common to the three PDE4D var- 
iants was obtained from the PDE4D2-pUC18 construct above-de- 
scribed using StuI and XbaI. These two fragments were ligated to- 
gether and inserted in the pCMV5 expression vector at EcoRI and 
XbaI sites. The complete sequences of the cDNAs were determined by 
the dideoxy chain termination method of Sanger, or by automatic 
sequencer (Beckman Center, Stanford University). The sequences of 
human PDE4D1, PDE4D2, PDE4D3 have been deposited in Gen- 
Bank under the following accession numbers: U50157, U50158, 
U50159. 
2.5. Transfection of 293 cells 
Human kidney 293 cells were transfected using the calcium phos- 
phate method, with 10-20 gg of pCMV5 human PDE4D2 or pCMV5 
human PDE4D3 plasmid per 10 cm dish, as previously described [34]. 
2.6. Western blot analysis 
The soluble extracts from transfected cells were immunoprecipitated 
by an anti-cAMP-PDE antiserum (K116) complexed to Pansorbin, as 
previously detailed [29]. K116 antiserum was raised against a peptide 
P2224 located at amino acid positions 105-126 of PDE4D1 and rec- 
ognizes the different PDE4A, PDE4B, PDE4D isoforms [32]. Immu- 
noadsorbed proteins were solubilized in 1% SDS in phosphate-buf- 
fered saline, subjected to SDS-PAGE and transferred to Immobilon 
membranes (Millipore) as described previously [29]. The cytosolic 
fraction of human blood mononuclear cells (approx. 5x 108 cells) 
was fractionated on a Mono Q HPLC column (Pharmacia) by using 
a 0.24).4 M NaC1 gradient in 50 mM Tris-HC1, pH 7.5, 1 mM 
EDTA, 7 mM 2-mercaptoethanol, pH 7.5. The phosphodiesterase 
activity of the fractions was measured as reported in [35] with 1 gM 
cAMP as substrate. The active fractions which were inhibited by 10 -5 
M rolipram were precipitated by trichloroacetic acid. For this pur- 
pose, 15 gl of 1% deoxycholate and 100 gl of 72% TCA were added 
per ml of eluate. After 30 min at 4°C, the pellets were neutralized with 
minute volumes of 1 M Tris. Alternatively, cAMP-PDEs present in 
human blood mononuclear cell extracts were immunoprecipitated as 
above. In both cases, proteins were subjected to SDS-PAGE and 
transferred to Immobilon membranes. Western blot analyses were 
performed by using as primary antibody either the anti-PDE4 anti- 
serum Kl16 or the anti-PDE4D monoclonal antibody M3S1 as pre- 
viously described [29]. M3S1 was raised against a fusion protein ob- 
tained by linking the glutathione transferase to the carboxy terminal 
region of rat PDE4D and specifically recognizes the PDE4D isoforms, 
as detailed in [36]. The immunoreactive bands were detected by an 
enhanced chemiluminescence m thod, following the manufacturer's 
protocol (Amersham). 
3. Results and discussion 
Oligodeoxynucleotide primers designed according to the 5' 
coding regions of the previously described rat PDE4D1, 
PDE4D2, PDE4D3 cDNAs were used to amplify mRNA 
from blood mononuclear  cells of human donors. PCR ampli- 
fication yielded f ra~nents  of the appropriate size, suggesting 
the expression of the human counterparts of the three rat 
PDE4D mRNAs in these cells (Fig. 1A). The primer pair 
A+C yielded the amplif ication of two DNA fragments, which 
fit the model proposed for the rat PDE4D1 and PDE4D2 
mRNA variants [26,27], the larger fragment corresponding 
to the rat var iant PDE4D1 (with intron A maintained) and 
the smaller fragment corresponding to the rat var iant 
PDE4D2 (with intron A spliced out). The presence of a se- 
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Fig. 3. Expression of human PDE4D2 and human PDE4D3 in transfected 293 ceils. Full length PDE4D2 and PDE4D3 cDNAs were subcloned 
in the eukaryotic expression vector pCMV5. 10-20 lag of pCMV5-PDE4D2 or pCMV5-PDE4D3 constructs were transfected into 293 cells. 
(A) PDE activity of the control and PDE-transfected cell cytosolic extracts. (B) Western blot analysis of the cytosolic extract from PDE-trans- 
fected cells: cyclic AMP-PDEs in the cell extracts were immunoprecipitated as described in section 2, and subjected to Western blot analysis by 
using the PDE4D-specific antibody M3S1. 
quence corresponding to intron A in a human mRNA was 
confirmed by using the primers B+C. The sequence of oligo- 
nucleotide B is included in intron A, and the only amplified 
fragment corresponds, in this case, to the 5' end of the human 
counterpart of rat PDE4D1 mRNA (Fig. 1A). The major 
band amplified with the primers D+COM2 corresponds to 
the amplification of the human PDE4D3 mRNA 5' end. 
The specificity of the amplifications was assessed by hybridi- 
zation of the DNA fragments to an internal oligonucleotide 
(Fig. 1B). The amplification of contaminating genomic DNA 
could be excluded by omission of reverse transcriptase and, in 
some cases, by using oligonucleotide C, which overlaps the 
boundary between exons 2 and 3. This primer can only anneal 
to the sequence corresponding to a mature mRNA with the 
intron between exons 2 and 3 spliced out [26]. 
The two DNA fragments amplified by primers A+C were 
subcloned and sequenced. The fragments showed high homol- 
ogy with the corresponding 5' end sequences of rat PDE4D1 
and rat PDE4D2 (Fig. 2). However, several base differences 
between human and rat sequences were observed, ruling out 
the possibility that an artifactual amplification of contami- 
nants had occurred. The differences were mainly clustered in 
the intron A sequence. The sequence of the fragment ampli- 
fied with the primers D+COM2 was identical to the human 
PDE4D3 sequence previously reported by others [22]. 
To obtain full length PDE4D2 cDNA, human blood mono- 
nuclear cell mRNA was amplified using the primers A+E as 
described in section 2. The ~ 1.7 kb fragment obtained was 
subcloned in the pCMV5 expression vector and sequenced. 
The amplified sequence included the entire ORF of human 
PDE4D2. A cDNA containing the entire ORF of human 
PDE4D3 was constructed by ligating an EcoRI-StuI frag- 
ment, corresponding to the PDE4D3 specific 5' end sequence, 
to a StuI-XbaI fragment corresponding to the sequence com- 
mon to all PDE4D variants. This cDNA was subcloned into 
the EcoRI and XbaI sites of pCMV5 vector polylinker and the 
complete sequence of the construct was determined. To verify 
whether the ORF present in these two cDNAs encoded active 
proteins, the corresponding expression vectors were used to 
transfect human kidney 293 cells. Both human PDE4D2 and 
PDE4D3 cDNAs induced the expression of high levels of 
PDE activity in transfected cells (Fig. 3). Western blot analy- 
sis, with a monoclonal anti-PDE4D antibody (M3S1), indi- 
cated the appearance of a 67 kDa protein in cells transfected 
with PDE4D2 cDNA, and of a 93 kDa protein in cells trans- 
fected with PDE4D3 cDNA (Fig. 3). Therefore, recombinant 
human PDE4D2 and PDE4D3 proteins have molecular 
weights identical to those previously determined for the cor- 
responding rat forms [27]. 
The cAMP phosphodiesterases expressed in human mono- 
nuclear cells, prepared from the blood of different healthy 
donors, were analyzed by Western blot using a polyclonal 
anti-PDE4 antibody (Kl l6)  and the monoclonal anti- 
PDE4D antibody M3S1 (Fig. 4). Although some differences 
from sample to sample were noticed, Western blot analysis of 
seven independent samples with antibody M3S1 indicated a 
predominant polypeptide of 72 kDa, corresponding to the 
molecular weight of PDE4D1, and a less abundant polypep- 
tide of 67 kDa, corresponding to the molecular weight of 
PDE4D2. Some unidentified polypeptides with a size smaller 
than PDE4D2 were also recognized. Among these bands, only 
the 72 kDa band, corresponding to PDE4D1, was recognized 
by the anti-PDE4 Kl l6 .  It is possible that expression of 
PDE4D2 is too low in these cells to be detected by this latter 
antibody. The anti-PDE4 K116 also recognized a band of 120 
kDa, which is not detected by M3S1, indicating that it is not a 
PDE4D isoform. The molecular weight of this PDE is similar 
to that predicted for PDE4A5 [22], and a band of similar size 
was recently detected in human U937 cells by using an anti- 
PDE4A antibody [37]. 
These data demonstrate hat short PDE4D variants are ex- 
pressed in human blood mononuclear cells. In the rat, expres- 
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Fig. 4. Western blot analysis of cytosolic extract from human blood mononuclear cells. Cyclic AMP-PDEs in the cell extract were either immu- 
noprecipitated or partially purified by HPLC as described in section 2, and analyzed by Western blotting using either the anti-PDE4 non-selec- 
tive antiserum Kl16, or the PDE4D-specific monoclonal antibody M3S1. This figure is representative of 7 independent experiments performed 
with different donors. Recombinant rat PDE4D1 and PDE4D3 proteins were loaded in parallel for comparison. 
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sion of these variants is under the control of an internal pro- 
moter regulated by cAMP [27,28]. Activation of this promoter 
and expression of the PDE4D1 and PDE4D2 variants are 
involved in the long-term adaptation and desensitization of
target cells to hormones. Our findings suggest hat a similar 
feedback loop could play a role in the control of intracellular 
cAMP levels in human blood mononuclear cells. This hypoth- 
esis is in agreement with a recent report describing the induc- 
tion of proteins very similar to PDE4D1 and PDE4D2 by 
cAMP in a human promonocytic cell line [38]. Furthermore, 
it has been shown that, in the rat, the cAMP regulation of the 
activity of the long PDE4D3 variant occurs at the post-trans- 
lational level, via a cAMP-dependent phosphorylation 
[27,29,30]. Studies with human U937 cells point to the absence 
of up-regulation of this variant by cAMP at the transcrip- 
tional level [37]. Moreover, in the same cell type, PDE4D3 
undergoes a short-term regulation by PKA-phosphorylation 
[31], which strongly suggests that its regulation is similar in 
human and rat. It is worth remarking that the pattern of 
splicing at the boundary of exon 2 has been conserved from 
rodents to humans, suggesting a physiological relevance for 
the differential regulation of protein variants arising from the 
PDE4D gene [27]. 
The newly identified human PDE4D1 and PDE4D2 lack 
the so-called UCR I (upstream conserved region I), a region 
of high homology with the drosophila dunce PDE sequence, 
which is present at the N-terminus in human and rat PDE4D3 
and other PDE4 variants [22,27,14]. Its strong conservation 
through evolution suggests an important function for this se- 
quence [22]. However, the existence of PDEs lacking this re- 
gion, in both rat and human, indicates that it is not essential 
for catalysis. The UCR I region may instead play a role in the 
regulation of enzyme activity. Indeed, consensus ites for 
PKA-mediated phosphorylation i  rat PDE4D3 reside within 
this region [39]. 
Our data indicate that, although the PDE4D3 mRNA is 
expressed in human blood mononuclear cells, the correspond- 
ing protein could not be detected with two different anti- 
PDE4 specific antibodies. This can be explained by a low 
translation rate of the PDE4D3 message, or by an expression 
restricted to a minor cell type, or alternatively by instability of 
the protein. The other PDE4D isoforms, and mainly 
PDE4D1, were present in amounts sufficient o be detected. 
A major isoform expressed in these cells can probably be 
identified as the product of a different gene, PDE4A5. 
Since blood mononuclear cells are mostly constituted of 
lymphocytes (85-90%), the pattern of PDE4 determined in 
the present study can be considered as representative of nor- 
mal human lymphocytes. In contrast to our results, a previous 
study has shown that in a human leukemic lymphocyte line 
expression of PDE4D3 mRNA could only be detected after 
dibutyryl cAMP treatment of the cells [40]. The presence of 
variants PDE4D1 and PDE4D2 was not addressed. However, 
it must be emphasized that leukemic transformation is known 
to be accompanied by an abnormal PDE expression [8]. 
Therefore, the PDE pattern of transformed lymphocytes 
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may not be representative of the actual repertoire of normal 
cells. 
In addition to lymphocytes, human blood mononuclear 
cells include a significant percentage of monocytes, that may 
participate in the PDE pattern we have determined. Previous 
studies on promonocytic cell lines pointed to the expression of 
PDE4D3 in unstimulated U937 cells [31,37,40], and to its 
absence in Mono Mac 6 cells [38]. The expression of other 
isoforms, namely PDE4D1, PDE4B2, and PDE4A5, was in- 
duced by cAMP-elevating agents in these cell lines [37,38,40]. 
Thus, there remains considerable uncertainty concerning the 
forms expressed in unstimulated normal human monocytes, 
and it is difficult to completely rule out the participation of 
this cell type to the isoenzyme xpression pattern we have 
determined from blood mononuclear cells. However, impor- 
tant differences between lymphocyte and monocyte PDE4 
profiles are suggested, mainly concerning the isoforms en- 
coded by genes PDE4B and PDE4D. Confirmation of this 
difference could open new avenues for selective pharmacolog- 
ical actions on a given cell type, by using isoenzyme-specific 
inhibitors. 
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